Exclusive Summary

• - Originator patents expired long ago; WHO EML inclusion makes injectable desmopressin broadly accessible with clear registration pathways.
• - Dual strengths (4 μg/mL and 15 μg/mL) align with weight-based dosing (0.3 μg/kg), improving perioperative convenience by minimizing infusion volume for adults and enabling precise pediatric titration.
• - Hospital-driven, multi-specialty demand across CDI, mild hemophilia A/Type 1 VWD, and uremic bleeding ensures steady, event-based usage.
• - Compared with factor replacement, single-dose cost savings are ≥90%; versus originator brands, typical generic price discounts are 30–70%.
• - Despite multiple generics, intermittent shortages and uneven strength coverage persist—reliable quality and full regulatory packages create a differentiated Distribution entry point.

Asset Materials

Contact Us for Full Materials